PTGS2 and Parkinson disease: The heterozygous mice have half the WT level of COX-2 [25], and this may explain the pharmacological benefits of reducing COX-2 activity because they exhibit less MPTP-induced Parkinson's disease-like pathology and symptoms as shown in this study.